Pharsight

Drugs that contain Cladribine

1. Mavenclad patents expiration

MAVENCLAD's oppositions filed in EPO
MAVENCLAD Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7888328 EMD SERONO INC Oral formulations of cladribine
Apr, 2024

(2 days ago)

US8785415 EMD SERONO INC Oral formulations of cladribine
Apr, 2024

(2 days ago)

US8377903 EMD SERONO INC Cladribine regimen for treating multiple sclerosis
May, 2026

(2 years from now)

US7713947 EMD SERONO INC Cladribine regimen for treating multiple sclerosis
Oct, 2026

(2 years from now)

US10849919 EMD SERONO INC Cladribine regimen for treating progressive forms of multiple sclerosis
Nov, 2038

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 29, 2022

Market Authorisation Date: 29 March, 2019

Treatment: Treatment of ms with a tablet with an admixture of (a) an amorphous inclusion complex of cladribine and hydroxypropyl-b-cyclodextrin and (b) amorphous free cladribine and cyclodextrin as a non-inclusi...

Dosage: TABLET;ORAL

How can I launch a generic of MAVENCLAD before it's drug patent expiration?
More Information on Dosage

MAVENCLAD family patents

Family Patents